Found 126 Lymphocytic Leukemia, Acute trials
A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Perceptions of Vaping Products
This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in …
Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector
This Phase 1/2 study will use a novel therapy, ARU-1801, for Sickle Cell Disease, using gene transfer of recombinant -globin lentivirus (LV) vector. The purpose of this study, which involves research, is to determine whether an experimental procedure called “gene transfer” is safe and effective. If you are interested in …
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
A Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
This study is being done to determine what effects the therapy venetoclax has on acute lymphoblastic leukemia (ALL).This investigational therapy will be added to what is a standard, liposomal vincristine, to treat relapsed ALL.
UPCC 04717: Phase I open label dose-escalation study to evaluate the safety expansion persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor) administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
The main aims of this study are to test the safety of up to 4 different doses of UCART19, and to identify the best dose of UCART19, by measuring what has happened to the leukemia cells at day 28 (28 days after the administration of UCART19), day 84 (84 days …
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
The Plea Trial(Posterior Wall and Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation)
The PLEA trial is designed to test the hypothesis whether posterior wall isolation (PWI) with pulmonary vein isolation (PVI), PWI plus left atrial appendage electrical isolation (LAAEI) with PVI and PWI plus LAAEI plus coronary sinus isolation (CSI) with PVI is superior to the standard approach alone (i.e. PVI alone) …
Please choose between Voice or SMS based delivery of verification code
or